1/10
Welcome to #TenPostNephJC
Can we move beyond slowing CKD → to actually repairing the kidney?
Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

excited for today’s AI in Kidney health primer @ Mount Sinai ! @asnkidney.bsky.social

a close up of a statue of yoda with the words `` learning you are '' written above him . ALT: a close up of a statue of yoda with the words `` learning you are '' written above him .

likewise! learning so much from yall ! #nephjc

nice work and great job hosting! #nephjc

i agree felt too short #nephjc

a man with glasses is making a funny face and says `` it has to be official , it has to be urine '' ALT: a man with glasses is making a funny face and says `` it has to be official , it has to be urine ''

urine donor derived cell free DNA 👀 #nephjc

a drawing of a prescription bottle with the words take your meds ALT: a drawing of a prescription bottle with the words take your meds

pill burden 😓

Janany Sabescumar Assoc Prof @ University of Rochester no coi #nephjc currently freezing 🥶

a man in a white shirt is dancing in front of a crowd ALT: a man in a white shirt is dancing in front of a crowd

💕💕 #nephjc

beautiful animation!!!

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients — NephJC This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

Hey #NephSky
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant

INFINITI: The Visual Abstract — NephJC SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in...

Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination

www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract

Up next on #NephJC we will be unpacking SGLT2i in transplant recipients👇

journals.lww.com/cja...

you are a hero 🙏

kpop and potassium enthusiast no COI 🥰 #nephjc

this is beyond creative, “My heart skips beats for K-pop—but potassium brings it back in sync.

POTCAST- K+ Pop and Arrhythmia Drop — NephJC This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast

welcome!

Good morning!

⏰2 hours until #NephJC chat
Join us today to learn more about the recently released VALIANT study, which investigates the use of Pegcetacoplan in C3 glomerulonephropathy and immune complex mediated glomerulonephritis

A VALIANT effort to combat complement disorders with pegcetacoplan — NephJC This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

Wilst thou join us here, where the Sky is Blue? #NephJC
On 1/13/26 at 9pm EST 'tis true
We shall converse of the great knight's quest,
a VALIANT effort from Sir Pegcetacoplan vs complement! ⚔️
www.nephjc.com/news/valiant-c3g

hahaha i really hope not!

Tis the season for christmas kidney cookies! Happy Holidays

1/10

Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC

We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less?

pubmed.ncbi.nlm.nih.gov/41201895/

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳
How soon should we withhold dialysis in AKI?
We're discussing the LIBERATE-D trial #NephSky
This one might just change your mind 🧠🧠
Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social
www.nephjc.com/news/liberated-aki

1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.

a man holds a bottle of snake oil in his hand ALT: a man holds a bottle of snake oil in his hand

food for thought!

Fish Oil in Dialysis: A Big Catch or an Empty Net — NephJC Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

Maybe the most shocking study from #KidneyWk.
🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC
Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊?
www.nephjc.com/news/pisces-fishoil

PISCES: The Visual Abstract — NephJC Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...

Holy Mackerel! 🐟
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva

Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙‍♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36